Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in "Exposed," a book that promises to shake the foundations of ...

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of ...

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median.

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss ...